Influenza virus like particles (VLPs): opportunities for H7N9 vaccine development
P Pushko, I Tretyakova - Viruses, 2020 - mdpi.com
In the midst of the ongoing COVID-19 coronavirus pandemic, influenza virus remains a
major threat to public health due to its potential to cause epidemics and pandemics with …
major threat to public health due to its potential to cause epidemics and pandemics with …
Targeting antigens for universal influenza vaccine development
Traditional influenza vaccines generate strain-specific antibodies which cannot provide
protection against divergent influenza virus strains. Further, due to frequent antigenic shifts …
protection against divergent influenza virus strains. Further, due to frequent antigenic shifts …
[HTML][HTML] Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus
Neuraminidase is the second major surface antigen on influenza virus. We investigated the
immunogenicity and cross protective efficacy of virus-like particle containing neuraminidase …
immunogenicity and cross protective efficacy of virus-like particle containing neuraminidase …
Vaccine-induced immunity elicited by microneedle delivery of influenza ectodomain matrix protein 2 virus-like particle (M2e VLP)-loaded PLGA nanoparticles
This study focused on developing an influenza vaccine delivered in polymeric nanoparticles
(NPs) using dissolving microneedles. We first formulated an influenza extracellular matrix …
(NPs) using dissolving microneedles. We first formulated an influenza extracellular matrix …
Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs
HJ Kang, KB Chu, DH Lee, SH Lee, BR Park, MC Kim… - PLoS …, 2019 - journals.plos.org
Despite the ability to induce a broad range of cross protection, M2e5x virus-like particles
(VLPs) alone provide limited vaccine efficacy and confer low efficacy of protection against …
(VLPs) alone provide limited vaccine efficacy and confer low efficacy of protection against …
M2e-based influenza vaccines with nucleoprotein: a review
Discovery of conserved antigens for universal influenza vaccines warrants solutions to a
number of concerns pertinent to the currently licensed influenza vaccines, such as annual …
number of concerns pertinent to the currently licensed influenza vaccines, such as annual …
Bacteriophage T4 vaccine platform for next-generation influenza vaccine development
M Li, P Guo, C Chen, H Feng, W Zhang, C Gu… - Frontiers in …, 2021 - frontiersin.org
Developing influenza vaccines that protect against a broad range of viruses is a global
health priority. Several conserved viral proteins or domains have been identified as …
health priority. Several conserved viral proteins or domains have been identified as …
Recombinant Bacillus subtilis flagellin Hag is a potent immunostimulant with reduced proinflammatory properties compared to Salmonella enterica serovar …
Flagellin constitutes a potential adjuvant for vaccines owing to its robust immunostimulatory
properties. However, clinical trials have revealed that flagellin derived from Salmonella …
properties. However, clinical trials have revealed that flagellin derived from Salmonella …
Generation and characterization of universal live-attenuated influenza vaccine candidates containing multiple M2e epitopes
Influenza viruses constantly evolve, reducing the overall protective effect of routine
vaccination campaigns. Many different strategies are being explored to design universal …
vaccination campaigns. Many different strategies are being explored to design universal …
Nanoscale mapping of recombinant viral proteins: from cells to virus-like particles
M Arista-Romero, P Delcanale, S Pujals… - ACS …, 2021 - ACS Publications
Influenza recombinant proteins and virus-like particles (VLPs) play an important role in
vaccine development (eg, CadiFlu-S). However, their production from mammalian cells …
vaccine development (eg, CadiFlu-S). However, their production from mammalian cells …